Chenguang Biotech Group

Chenguang Biotech has released its 2026 interim report, showing net profit attributable to the parent company of 179 million yuan, a decrease of 16.95% compared with the same period last year. Total operating revenue was 3.159 billion yuan, down 13.63% year-on-year. Net cash inflow from operating activities was 1.218 billion yuan, down 33.43% year-on-year. The latest asset-liability ratio was 64.06%, gross margin was 13.46%, return on equity was 5.25%, and diluted earnings per share was 0.37 yuan.

Chenguang Biotech Group Co., Ltd. has been issued a warning letter by the Xinjiang Securities Regulatory Bureau for constituting a non-operating fund occupation of Xinjiang Shengyuan Biotech Co., Ltd. Upon investigation, from March to April 2025, Chenguang Biotech received a total of 136 million yuan in intercompany loans from Tumushuke Shengyuan Biotech Co., Ltd. and Kashgar Shengyuan Biotech Co., Ltd., both wholly-owned subsidiaries of Shengyuan Biotech, as well as from Handan Chenguang Plant Protein Co., Ltd. The funds were repaid with interest in May 2025.